Bipolar Androgen Therapy: A Paradoxical Approach for the Treatment of Castration-resistant Prostate Cancer

Michael T. Schweizer; Emmanuel S. Antonarakis; Samuel R. Denmeade

doi:10.1016/j.eururo.2017.03.022

Bipolar Androgen Therapy: A Paradoxical Approach for the Treatment of Castration-resistant Prostate Cancer

Michael T. Schweizer
, Emmanuel S. Antonarakis
, Samuel R. Denmeade

Research output: Contribution to journal › Editorial › peer-review

20 Scopus citations

Abstract

Bipolar androgen therapy (BAT) is a paradoxical treatment for castrate-resistant prostate cancer whereby testosterone levels are rapidly alternated between supraphysiologic and near-castrate concentrations. Initial studies demonstrated that BAT is safe and produces clinical responses. A trial comparing enzalutamide against BAT is ongoing.

Original language	English (US)
Pages (from-to)	323-325
Number of pages	3
Journal	European Urology
Volume	72
Issue number	3
DOIs	https://doi.org/10.1016/j.eururo.2017.03.022
State	Published - Sep 2017
Externally published	Yes

Bibliographical note

Publisher Copyright:
© 2017 European Association of Urology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Publisher link

10.1016/j.eururo.2017.03.022

Find It

Find It at U of M Libraries

Cite this

@article{1a4a446912134716973d77b1a86619f8,

title = "Bipolar Androgen Therapy: A Paradoxical Approach for the Treatment of Castration-resistant Prostate Cancer",

abstract = "Bipolar androgen therapy (BAT) is a paradoxical treatment for castrate-resistant prostate cancer whereby testosterone levels are rapidly alternated between supraphysiologic and near-castrate concentrations. Initial studies demonstrated that BAT is safe and produces clinical responses. A trial comparing enzalutamide against BAT is ongoing.",

author = "Schweizer, \{Michael T.\} and Antonarakis, \{Emmanuel S.\} and Denmeade, \{Samuel R.\}",

note = "Publisher Copyright: {\textcopyright} 2017 European Association of Urology",

year = "2017",

month = sep,

doi = "10.1016/j.eururo.2017.03.022",

language = "English (US)",

volume = "72",

pages = "323--325",

journal = "European Urology",

issn = "0302-2838",

publisher = "Elsevier B.V.",

number = "3",

}

TY - JOUR

T1 - Bipolar Androgen Therapy

T2 - A Paradoxical Approach for the Treatment of Castration-resistant Prostate Cancer

AU - Schweizer, Michael T.

AU - Antonarakis, Emmanuel S.

AU - Denmeade, Samuel R.

PY - 2017/9

Y1 - 2017/9

N2 - Bipolar androgen therapy (BAT) is a paradoxical treatment for castrate-resistant prostate cancer whereby testosterone levels are rapidly alternated between supraphysiologic and near-castrate concentrations. Initial studies demonstrated that BAT is safe and produces clinical responses. A trial comparing enzalutamide against BAT is ongoing.

AB - Bipolar androgen therapy (BAT) is a paradoxical treatment for castrate-resistant prostate cancer whereby testosterone levels are rapidly alternated between supraphysiologic and near-castrate concentrations. Initial studies demonstrated that BAT is safe and produces clinical responses. A trial comparing enzalutamide against BAT is ongoing.

UR - https://www.scopus.com/pages/publications/85016546537

UR - https://www.scopus.com/pages/publications/85016546537#tab=citedBy

U2 - 10.1016/j.eururo.2017.03.022

DO - 10.1016/j.eururo.2017.03.022

M3 - Editorial

C2 - 28365160

AN - SCOPUS:85016546537

SN - 0302-2838

VL - 72

SP - 323

EP - 325

JO - European Urology

JF - European Urology

IS - 3

ER -

Bipolar Androgen Therapy: A Paradoxical Approach for the Treatment of Castration-resistant Prostate Cancer

Abstract

Bibliographical note

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this